Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:IOVA NASDAQ:MIRM NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.67$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsIOVAIovance Biotherapeutics$3.50-1.5%$3.81$1.64▼$5.63$1.56B0.6915.31 million shs9.67 million shsMIRMMirum Pharmaceuticals$109.41+6.3%$93.79$42.89▼$112.00$6.67B0.52849,790 shs1.11 million shsPTGXProtagonist Therapeutics$99.91+1.1%$99.40$42.85▼$107.84$6.39B1.89769,875 shs125,890 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.24%+69.15%+117.36%IOVAIovance Biotherapeutics-13.20%+5.65%+6.93%+40.32%+13.42%MIRMMirum Pharmaceuticals-6.50%+5.78%+7.61%+2.45%+149.71%PTGXProtagonist Therapeutics-4.92%-0.12%-4.72%+17.00%+129.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.67$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsIOVAIovance Biotherapeutics$3.50-1.5%$3.81$1.64▼$5.63$1.56B0.6915.31 million shs9.67 million shsMIRMMirum Pharmaceuticals$109.41+6.3%$93.79$42.89▼$112.00$6.67B0.52849,790 shs1.11 million shsPTGXProtagonist Therapeutics$99.91+1.1%$99.40$42.85▼$107.84$6.39B1.89769,875 shs125,890 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.24%+69.15%+117.36%IOVAIovance Biotherapeutics-13.20%+5.65%+6.93%+40.32%+13.42%MIRMMirum Pharmaceuticals-6.50%+5.78%+7.61%+2.45%+149.71%PTGXProtagonist Therapeutics-4.92%-0.12%-4.72%+17.00%+129.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.11Hold$111.87-2.78% DownsideIOVAIovance Biotherapeutics 2.33Hold$8.63146.78% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$136.4224.69% UpsidePTGXProtagonist Therapeutics 2.80Moderate Buy$113.6913.79% UpsideCurrent Analyst Ratings BreakdownLatest IOVA, ACLX, MIRM, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$128.00 ➝ $142.005/7/2026MIRMMirum Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$125.00 ➝ $145.005/7/2026MIRMMirum Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$165.005/7/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$185.005/7/2026MIRMMirum Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$138.005/7/2026MIRMMirum Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$136.005/7/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.005/7/2026MIRMMirum Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $129.005/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026PTGXProtagonist Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$120.00 ➝ $137.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$22.29M301.95N/AN/A$6.96 per share16.53IOVAIovance Biotherapeutics$263.50M5.92N/AN/A$1.76 per share1.99MIRMMirum Pharmaceuticals$521.31M12.80$0.05 per share2,159.32$6.12 per share17.88PTGXProtagonist Therapeutics$74.06M86.75N/AN/A$10.19 per share9.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$228.93M-$4.07N/AN/AN/A-1,027.26%-55.42%-36.24%N/AIOVAIovance Biotherapeutics-$390.98M-$1.12N/AN/AN/A-148.41%-54.54%-42.36%N/AMIRMMirum Pharmaceuticals-$23.36M-$0.48N/AN/AN/A-140.24%-10.84%-3.97%N/APTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%N/ALatest IOVA, ACLX, MIRM, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.3940-$13.43-$13.0360-$13.43$148.21 million$159.88 million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million2/26/2026Q4 2025ACLXArcellx-$1.01-$1.01N/A-$1.01$13.40 million$1.65 million2/25/2026Q4 2025MIRMMirum Pharmaceuticals$0.02-$0.11-$0.13-$0.12$141.78 million$148.93 million2/25/2026Q4 2025PTGXProtagonist Therapeutics-$0.53-$0.69-$0.16-$0.69$14.92 million$7.44 million2/24/2026Q4 2025IOVAIovance Biotherapeutics-$0.22-$0.18+$0.04-$0.18$81.61 million$86.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.444.44IOVAIovance BiotherapeuticsN/A3.202.83MIRMMirum Pharmaceuticals0.982.672.55PTGXProtagonist TherapeuticsN/A17.7612.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%IOVAIovance Biotherapeutics77.03%MIRMMirum PharmaceuticalsN/APTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%IOVAIovance Biotherapeutics10.30%MIRMMirum Pharmaceuticals14.36%PTGXProtagonist Therapeutics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8058.48 million53.60 millionOptionableIOVAIovance Biotherapeutics500446.50 million400.51 millionOptionableMIRMMirum Pharmaceuticals14060.98 million52.22 millionOptionablePTGXProtagonist Therapeutics12064.31 million61.15 millionOptionableIOVA, ACLX, MIRM, and PTGX HeadlinesRecent News About These CompaniesIs It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?May 7 at 7:32 AM | finance.yahoo.comProtagonist Therapeutics (NASDAQ:PTGX) Given New $137.00 Price Target at Citizens JmpMay 7 at 4:20 AM | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Given New $118.00 Price Target at WedbushMay 7 at 4:20 AM | americanbankingnews.comProtagonist Therapeutics: Q1 Earnings SnapshotMay 6 at 4:30 PM | chron.comProtagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $137.00May 6 at 11:48 AM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Wedbush Analyst SaysMay 6 at 8:49 AM | marketbeat.comVanguard Group Inc. Purchases 1,156,461 Shares of Protagonist Therapeutics, Inc. $PTGXMay 6 at 8:14 AM | marketbeat.comProtagonist Therapeutics: Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5 at 11:17 PM | finanznachrichten.deProtagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPSMay 5 at 7:21 PM | marketbeat.comProtagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5 at 4:05 PM | accessnewswire.comAProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from BrokeragesMay 5 at 2:10 AM | americanbankingnews.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from AnalystsMay 5 at 2:07 AM | marketbeat.comProtagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This StockMay 2, 2026 | insidermonkey.com331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLCMay 2, 2026 | marketbeat.comM&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGXMay 1, 2026 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Design Therapeutics (DSGN) and Protagonist Therapeutics (PTGX)April 30, 2026 | theglobeandmail.comPictet Asset Management Holding SA Has $46.26 Million Stock Position in Protagonist Therapeutics, Inc. $PTGXApril 30, 2026 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Sold by Moody Aldrich Partners LLCApril 29, 2026 | marketbeat.comUBS Group AG Acquires 874,013 Shares of Protagonist Therapeutics, Inc. $PTGXApril 29, 2026 | marketbeat.comProtagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comProtagonist Therapeutics: Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda CollaborationApril 29, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOVA, ACLX, MIRM, and PTGX Company DescriptionsArcellx NASDAQ:ACLX$115.07 0.00 (0.00%) As of 04/28/2026Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Iovance Biotherapeutics NASDAQ:IOVA$3.50 -0.06 (-1.55%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Mirum Pharmaceuticals NASDAQ:MIRM$109.41 +6.48 (+6.29%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Protagonist Therapeutics NASDAQ:PTGX$99.91 +1.06 (+1.07%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
